drugset

drugset / Trial / NCT04540016

Mass Balance and Biotransformation of [14C]HSK7653 in Human

NCT04540016 ↗

Phase 1 Completed 6 enrolled Sichuan Haisco Pharmaceutical Group Co., Ltd First Affiliated Hospital of Suzhou Medical College · collab

NaSingle-groupOpen-labelTreatment

Summary

A single-center, single-dose, non-randomized, open-label design.

Timeline

Start: 2020-11-15
Primary completion: 2021-01-14
Completion: 2021-01-21

Publications

Bian YC, Meng J, Hu T, Ma S, Huang CR, Zhang FY, Wu QH, Zhang H, Chen XY, Miao LY. Biotransformation and disposition characteristics of HSK7653, a novel long-acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Diabetes Obes Metab. 2024 Jul;26(7):2860-2868. doi: 10.1111/dom.15605. Epub 2024 Apr 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK7653	Unknown	25 mg	Oral

Indications